Ceftazidime in patients with Pseudomonas infections

Area of Science:

• Infectious Diseases
• Pharmacology
• Clinical Microbiology

Background:

• Serious bacterial infections pose significant therapeutic challenges.
• Pseudomonas aeruginosa is a common cause of hospital-acquired infections.
• Ceftazidime is a third-generation cephalosporin antibiotic with broad-spectrum activity.

Purpose of the Study:

• To evaluate the clinical efficacy and microbiological impact of ceftazidime in patients with serious infections.
• To assess the development of antimicrobial resistance during ceftazidime therapy.
• To document adverse reactions associated with ceftazidime treatment.

Main Methods:

• Prospective study involving 41 patients with serious bacterial infections.
• Ceftazidime administered to patients with infections caused by Pseudomonas aeruginosa or other bacteria.
• Clinical response, microbiological eradication, resistance development, and adverse events were monitored.

Main Results:

• High clinical response rates observed for both Pseudomonas aeruginosa (88%) and other bacterial infections (94%).
• Microbiological eradication rates were comparable: 83% for Pseudomonas and 82% for non-Pseudomonas strains.
• Ceftazidime resistance emerged in 3 cases; one case of superinfection with resistant Enterobacter agglomerans occurred.
• Adverse reactions included leukopenia, azotaemia, diarrhea (Clostridium difficile positive), and rash.

Conclusions:

• Ceftazidime is an effective treatment for serious infections caused by Pseudomonas aeruginosa and other bacteria.
• The development of resistance and superinfections is infrequent but warrants monitoring.
• Ceftazidime is generally well-tolerated, with most adverse events being clinically manageable.